Document Detail


Nanomedicine for uterine leiomyoma therapy.
MedLine Citation:
PMID:  23343157     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: The purpose of this work was to engineer polymeric nanoparticles to encapsulate and deliver 2-methoxyestradiol, a potential antitumor drug for treatment of uterine leiomyoma (fibroids), the most common hormone-dependent pathology affecting women of reproductive age.
METHODS/RESULTS: Encapsulation efficiency and drug release from the nanoparticles were monitored by HPLC. Cell morphology and in vitro cytotoxicity experiments were carried out in a human leiomyoma cell line. The nanoparticles displayed high encapsulation efficiency (>86%), which was verified by differential scanning calorimetry and x-ray diffraction. Excellent long-term stability of the nanoparticles and gradual drug release without burst were also observed. Cellular uptake of fluorescent nanoparticles was confirmed by confocal imaging. The drug-loaded poly(lactic acid) and poly(lactic-co-glycolic acid) nanoparticles induced cytotoxicity in human leiomyoma cells to a significantly greater extent than the free drug at 0.35 µM.
CONCLUSION: This novel approach represents a potential fertility-preserving alternative to hysterectomy.
Authors:
Hazem Ali; Gokhan Kilic; Kathleen Vincent; Massoud Motamedi; Erik Rytting
Related Documents :
17891577 - Pharmaceutical applications of hot-melt extrusion: part i.
20926087 - Evaluation of the enantioselectivity of glycogen-based dual chiral selector systems tow...
23162427 - Neuroplasticity in addiction: cellular and transcriptional perspectives.
23226017 - Detection of nanolevel drug metabolites in an organotypic culture of primary human hepa...
1526077 - Intravenous nicotine retards transdermal absorption of nicotine: evidence of blood flow...
22760517 - Pharmacogenetics of osteoporosis: what is the evidence?
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Validation Studies    
Journal Detail:
Title:  Therapeutic delivery     Volume:  4     ISSN:  2041-5990     ISO Abbreviation:  Ther Deliv     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-24     Completed Date:  2013-03-07     Revised Date:  2014-02-04    
Medline Journal Info:
Nlm Unique ID:  101538870     Medline TA:  Ther Deliv     Country:  England    
Other Details:
Languages:  eng     Pagination:  161-75     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Calorimetry, Differential Scanning
Cell Line, Tumor
Chromatography, High Pressure Liquid
Drug Carriers / chemistry
Drug Stability
Drug Storage
Estradiol / administration & dosage,  analogs & derivatives*,  pharmacokinetics,  pharmacology
Female
Humans
Lactic Acid / chemistry
Leiomyoma / drug therapy*,  pathology
Nanomedicine / methods
Nanoparticles*
Polyglycolic Acid / chemistry
Polymers / chemistry
Time Factors
Tubulin Modulators / administration & dosage,  pharmacokinetics,  pharmacology
Uterine Neoplasms / drug therapy*,  pathology
X-Ray Diffraction
Grant Support
ID/Acronym/Agency:
K12 HD052023/HD/NICHD NIH HHS; K12HD052023/HD/NICHD NIH HHS
Chemical
Reg. No./Substance:
0/Drug Carriers; 0/Polymers; 0/Tubulin Modulators; 0/polylactic acid-polyglycolic acid copolymer; 26009-03-0/Polyglycolic Acid; 26100-51-6/poly(lactic acid); 33X04XA5AT/Lactic Acid; 4TI98Z838E/Estradiol; 6I2QW73SR5/2-methoxyestradiol
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Research Spotlight: Nanomedicines for HIV therapy.
Next Document:  Effervescent redispersion of lyophilized polymeric nanoparticles.